The in vitro antibacterial activity of DU-6681a, a parent compound of DZ-2640, against gram-positive and -negative bacteria was compared with those of penems and cephalosporins currently available. MICs at which 90% of the isolates are inhibited (MIC 90 s) of the compound for clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-susceptible and -resistant strains, were 0.10, 25, and 12.5 g/ml, respectively. DU-6681a inhibited the growth of all strains of Streptococcus pyogenes and of penicillin-susceptible and -insusceptible Streptococcus pneumoniae at 0.006, 0.025, and 0.20 g/ml, respectively, and MIC 90 s of the compound were 6.25 and >100 g/ml for Enterococcus faecalis and Enterococcus faecium, respectively. MIC 90 s of DU-6681a were 0.20, 0.10, and 0.025 g/ml for Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae, respectively. For Pseudomonas aeruginosa, the MIC 50 and MIC 90 of DU-6681a were 25 and 50 g/ml, respectively. DU-6681a activity was not affected by different media, varied inoculum size (10 4 to 10 7 CFU), or the addition of human serum but was decreased under acidic conditions against gram-negative bacteria, under alkaline conditions against gram-positive bacteria, and in human urine, as was the activity of the other antibiotics tested. The frequency of spontaneous resistance to DU-6681a was less than or equal to those of the reference compounds. Time-kill curve studies demonstrated the bactericidal action of DU-6681a against S. aureus, S. pneumoniae, Escherichia coli, and H. influenzae.
DZ-2640 is a new oral carbapenem having a bicyclic imidazole ring as a side chain (Fig. 1) . The bicyclic imidazole ring system influenced both in vitro activity and pharmacokinetics after oral administration as pivaloyloxymethyl (POM) ester prodrug in rats (10) ; orally administrated DZ-2640 was reported to be rapidly absorbed in mice, rats, monkeys, and dogs as potent drug (1) . DU-6681 is a parent compound of DZ-2640 and DU-6681a is a sodium salt of DU-6681. In this study, we compared the antimicrobial activity of DU-6681a with those of oral penems and cephalosporins such as furopenem (3, 4) , cefpodoxime (5, 15) , and cefdinir (9) against freshly isolated bacteria and estimated the effect of growth conditions on the activity of DU-6681a and its ␤-lactamase stability. Cefpodoxime and cefdinir were brought to market in 1989 and 1993 in Japan, respectively, and there are no oral carbapenems on the market yet. The standard MIC method for determining antibacterial activity provides no information on initial killing kinetics. This study therefore includes the killing curve method to obtain additional information on the antibacterial properties of DU-6681a in vitro, particularly with regard to its initial bactericidal activity against selected strains. The morphological study using differential interference microscopy also provides additional information on its bactericidal activity.
MATERIALS AND METHODS
Antibacterial agents. DU-6681a, a parent compound of DZ-2640, and furopenem (3, 4) , cefpodoxime (5, 15) , cefdinir (9) , GV-104326, imipenem, and cefaclor were synthesized at the New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan. Methicillin sodium (Sigma Chemical Co., St. Louis, Mo.) and ampicillin (Sigma) were obtained commercially.
Organisms. Thirty-one aerobic and 26 anaerobic standard strains stocked in the New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., were used. A total of 643 strains, isolated between 1990 and 1994 from patients at six medical centers located in the Tokyo and Tohoku areas in Japan were randomly used (one isolate per patient). The two reference strains Escherichia coli NIH JC-2 and Staphylococcus aureus FDA 209-P were included as internal controls throughout the study.
Determination of MICs. The MICs for standard strains were determined by the broth microdilution method with Mueller-Hinton broth (MHB; Difco Laboratories, Detroit, Mich.) for aerobic strains or GAM broth (Nissui Seiyaku Co., Ltd., Tokyo, Japan) for anaerobic strains. MICs for clinical strains were determined by the agar dilution method (8) with Mueller-Hinton agar (MHA; Difco). MHA supplemented with 5% horse blood (chocolate agar) was used for streptococci, Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae, while GAM agar (Nissui) was used for Bacteroides fragilis (11) . One loopful (5 l) of an inoculum corresponding to 10 4 CFU per spot was inoculated on drugcontaining agar plates, and the plates were incubated for 18 h at 37°C, except those with B. fragilis, which were incubated for 24 h. H. influenzae and N. gonorrhoeae were incubated under conditions of 10% CO 2 , and B. fragilis was incubated in an anaerobic cabinet. The MIC was defined as the lowest drug concentration which prevented visible growth of bacteria. Tests to examine the effects of varied inoculum size and medium pH, as well as of the addition of human serum on DU-6681a activity, were also performed by the MHA dilution method. The effect of the type of medium was determined by the agar dilution method using nutrient agar (NA; Eiken Chemical Co., Ltd., Tokyo, Japan), tryptone soy agar (TSA; Eiken), heart infusion agar (HIA; Eiken), brain heart infusion agar (BHIA; Difco), and MHA. The effect of human urine was examined by the macrodilution tube method (15) using MHB or 100% human urine. The final inoculum size was 5 ϫ 10 5 CFU/ml. Frequency of spontaneous resistant mutants. The test strains were precultured in MHB for 20 h at 37°C. The bacterial suspension was plated onto MHA plates containing 2, 4, or 8 times the MIC of each compound. After 48 h at 37°C, colonies were counted and the frequency of spontaneous resistance was calculated as the ratio of the number of colonies that grew on drug-containing plates to those on drug-free plates.
Determination of bactericidal activity. The organisms incubated in MHB for 18 h at 37°C were diluted with fresh broth to about 10 5 CFU/ml, and the diluted cultures were then incubated with agitation for 2 h at 37°C. For H. influenzae, MHB supplemented with 5% Fildes enrichment was used. After this preincubation, cultures were incubated in the absence of the indicated drug or in its presence at levels equivalent to one-quarter, one-half, one, two, and four times the MIC, and samples were removed at intervals, serially diluted, and plated for viable cells. The colonies were counted after 24 h of incubation at 37°C. Samples of bacterial suspensions used in the above-mentioned experiment were observed by differential interference microscopy.
␤-Lactamase stability. Cell sonic extracts which were prepared from lateexponential cultures in MHB were used as enzyme solutions. Stability to ␤-lactamases from Stenotrophomonas maltophilia was measured with purified group 3 (L-1) and 2e (L-2) ␤-lactamases (2, 12) . Hydrolytic rates of ␤-lactams were measured by a modified spectrophotometric method with 100 M substrate at 30°C (6, 14) .
Kinetic analysis of ␤-lactamases. K m and maximum rate of metabolism (V max ) values were determined from hydrolytic rates of various concentration of substrates by using a Lineweaver-Burk plot with an enzyme preparation partially purified by DEAE-Cephacel and Sephadex G-50. The inhibitory constant (K i ), with cephaloridine or penicillin G as the substrate, was determined by using a Dixon plot.
Stability to DHP-I. The susceptibility of DU-6681a to renal dehydropeptidase-I (DHP-I) was compared with that of imipenem by using partially purified swine renal DHP-I. Hydrolytic rates of compounds were measured by a modified spectrophotometric method with 100 M substrate at 30°C (7). The relative hydrolysis rate was determined, taking the hydrolysis rate of imipenem as 100. Bactericidal kinetics of DU-6681a. MICs (å) were 0.025 g/ml for S. aureus, 0.013 g/ml for S. pneumoniae, 0.013 g/ml for E. coli, and 0.10 g/ml for H. influenzae. Symbols: ᮀ, control; E, one-quarter the MIC; Ç, one-half the MIC; F, twice the MIC; s, four times the MIC. 
RESULTS
Antibacterial activity. The antimicrobial spectra of DU-6681a and reference antibiotics against individual aerobic and anaerobic strains are shown in Tables 1 and 2 . DU-6681a was found to possess antibacterial activity against a wide range of bacteria. Tables 3 and 4 compare the activity of DU-6681a against groups of clinical isolates of gram-positive and -negative bacteria with those of the reference compounds. The MIC 90 s of DU-6681a for methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA) (MIC of methicillin, Ն12.5 g/ml), and S. epidermidis were 0.10, 25, and 12.5 g/ml, respectively. The activity against MSSA was 2-to 64-fold higher than those of the other reference compounds at MIC 90 s. DU-6681a showed the highest activity against S. aureus and S. epidermidis among the antibiotics tested. MIC 90 s for Streptococcus pyogenes and penicillin-susceptible and -insusceptible S. pneumoniae were 0.006, 0.025, and 0.20 g/ml, respectively. For Enterococcus faecalis and Enterococcus faecium, the MIC 90 s of DU-6681a were 6.25 and Ͼ100 g/ml, respectively.
Against various species of Enterobacteriaceae, DU-6681a was at least fourfold more active than the reference compounds. DU-6681a inhibited 90% of isolates of E. coli, Enterobacter cloacae, Klebsiella pneumoniae, and Morganella morganii at Յ0.20 g/ml and inhibited 90% of isolates of Citrobacter freundii, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, and Providencia stuartii at 6.25, 0.10, 0.39, 1.56, and 0.78 g/ml, respectively. DU-6681a showed potent activity against cephalosporin-and/or penem-resistant E. cloacae. For Pseudomonas aeruginosa, MIC 90 s of all compounds showed were greater than 50 g/ml. Other glucose-nonfermentable gram-negative bacteria, including Alcaligenes faecalis, Alcaligenes denitrificans, and Acinetobacter calcoaceticus, were mostly susceptible to DU-6681a (MIC 90 , 6.25 g/ml).
H. influenzae, including ␤-lactamase-producing strains, M. catarrhalis, and N. gonorrhoeae were susceptible to DU-6681a, with MIC 90 s for these strains being 0.20, 0.10, and 0.025 g/ml, respectively. The MIC 50 and MIC 90 of DU-6681a for B. fragilis were 0.20 and 1.56 g/ml, respectively.
The reference MICs of DU-6681a for E. coli NIH JC-2 and S. aureus FDA 209-P control strains were 0.006 and 0.013 g/ml, respectively.
Factors affecting activity. The activities of DU-6681a against S. aureus FDA 209-P, S. epidermidis 56556, E. coli NIH JC-2, K. pneumoniae type I, and P. aeruginosa PAO1 were closely similar in all five different media tested, namely, MHA, NA, HIA, BHIA, and TSA (data not shown). Varying the pH of MHA between 7 and 8.5, adding human serum of 10, 25, and 50% to the medium, increasing the inoculum size from 10 4 to 10 7 CFU, or the presence of inoculum in human urine had no significant effect on the activity of DU-6681a against each strain, except for a fourfold increase in the MIC for S. epidermidis at pH 8.5. However, activity in the pH 5.5 MHA was 4-fold higher than that in the pH 7.0 MHA against staphylococci and 8-and 16-fold lower against E. coli and K. pneumoniae, respectively, than were activities of the other drugs tested.
Frequency of spontaneous resistant mutants. The frequencies of spontaneous resistance at two, four, and eight times the MIC of each drug are shown in Table 5 . The frequencies of spontaneous resistance to DU-6681a were lower than those to the comparator compounds except for S. aureus P. aeruginosa (50) DU-6681a 3.13-Ͼ100 25 50 Furopenem 25-Ͼ100 Ͼ100 Ͼ100 GV104326 12.5-Ͼ100 100 Ͼ100 Cefpodoxime Ͼ100 Ͼ100 Ͼ100 Cefdinir Ͼ100 Ͼ100 Ͼ100
S. maltophilia (23) DU-6681a Ͼ100 Ͼ100 Ͼ100 Furopenem Ͼ100 Ͼ100 Ͼ100 Cefpodoxime Ͼ100 Ͼ100 Ͼ100 Cefdinir Ͼ100 Ͼ100 Ͼ100
Continued on following page KL-16, and furopenem (1.0 ϫ 10
Ϫ6
) and cefdinir (1.3 ϫ 10 Ϫ6 ) against K. pneumoniae type I resulted in higher frequencies of resistance than did the other compounds. Except for the five cases mentioned above, there were no significant differences in the frequencies of resistance to the antibiotics tested.
Bactericidal activity. Killing curve studies showed rapid bactericidal activity of DU-6681a against S. aureus FDA 209-P, S. pneumoniae 57664, and E. coli KL-16 at the concentrations higher than the MIC (Fig. 2) . However, in the case of H. influenzae, viable cell counts decreased only 1/10 of initial counts after a 6-h exposure to DU-6681a at concentrations one, two, and four times the MIC. Morphological alteration of E. coli after exposure to DU-6681a is shown in Fig. 3 and 4 . E. coli cells became ovoid at concentrations one-eighth to eight times the MIC, while filamentous cells were observed after exposure to cefdinir.
Stability to ␤-lactamase and DHP-I. The ␤-lactamase stabilities of the antibiotics tested are shown in Table 6 . DU6681a was stable to various types of ␤-lactamases except S. maltophilia type 3 enzyme and showed potent antimicrobial activity against ␤-lactamase-producing strains except S. maltophilia and P. aeruginosa. The relative hydrolysis rate of DU6681a by renal DHP-I was 6, while the hydrolysis rate of imipenem was defined as 100.
Kinetic analysis of ␤-lactamases. Table 6 
DISCUSSION
This study showed that DU-6681a, a recently discovered oral carbapenem, possesses antibacterial activities against staphylococci and streptococci more potent than those of furopenem, cefpodoxime, and cefdinir. The highly antibacterial activity of furopenem against penicillin-susceptible and -resistant S. pneumoniae was reported by Spangler et al. (13) , whose MIC 50 s and MIC 90 s of furopenem were similar to ours. Moreover, DU6681a showed a potent activity against Enterobacteriaceae, H. influenzae, M. catarrhalis, and N. gonorrhoeae, which are known as significant pathogens in clinical fields.
Time-kill curve studies showed the rapid bactericidal action of DU-6681a against S. aureus, S. pneumoniae, and E. coli. Its bactericidal activity against H. influenzae is noteworthy. The bactericidal activity of DU-6681a was higher than that of the other compound tested (data not shown). Morphological alterations of E. coli exposed to DU-6681a were different from those of E. coli exposed to cefdinir. Ovoid cells were observed, suggesting that DU-6681a might have a high affinity for penicillin-binding protein 2 of E. coli.
DU-6681a was not hydrolyzed by various types of ␤-lactamases, including the extended-spectrum ␤-lactamases TEM-3 and -7, some of which hydrolyzed oxyiminocephalosporin antibiotics. This high stability of the compound to ␤-lactamases contributed to its potent antibacterial activity against the ␤-lac- tamase-producing strains tested. However, S. maltophilia L-1 enzyme, which is a metalloenzyme, hydrolyzed DU-6681a as well as other ␤-lactams, including furopenem (4). K i values of DU-6681a for ␤-lactamases were lower than those of furopenem except for the enzyme from E. coli 1154. This indicates that DU-6681a has a high affinity for and a high stability to ␤-lactamases.
Final decisions on the apparently greater efficacy of DU6681a compared with other ␤-lactams must await further studies, such as studies of affinity for penicillin-binding proteins, studies of efficacy for animal models, pharmacokinetic and toxicity studies, and clinical evaluations.
